Evidence map›Paper›PMID 42315574›Full record

ArticleScientific reports2026

BDNF rs6265 polymorphism is not associated with the occurrence of overactive bladder and its response to intradetrusor injection of botulinum neurotoxin type A in female patients.

Sylwester Michał Ciećwież, Klaudyna Lewandowska, Agnieszka Boroń, Dariusz Kotlęga, Jacek Kociszewski, Katarzyna Grocholewicz, Jeremy S Clark, Andrzej Ciechanowicz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sylwester Michał CiećwieżDepartment of Perinatology, Obstetrics and Gynecology, Pomeranian Medical University, Szczecin, Poland.
Klaudyna LewandowskaDepartment of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland.
Agnieszka BorońDepartment of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland.
Dariusz KotlęgaDepartment of Pharmacology and Toxicology, University of Zielona Góra, Zielona Góra, Poland.
Jacek KociszewskiDepartment of Gynecology, Evangelisches Krankenhaus Hagen, Hagen, Germany.
Katarzyna GrocholewiczDepartment of Interdisciplinary Dentistry, Pomeranian Medical University, Szczecin, Poland.
Jeremy S ClarkDepartment of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland.
Andrzej CiechanowiczDepartment of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland. andrzej.ciechanowicz@pum.edu.pl.

Funding

Polish Minister of Science and Higher Education 002/RID/2018/19
6 · The paper itself

Abstract

Reports suggest increased urinary excretion of Brain-Derived Neurotrophic Factor in patients with Overactive Bladder (OAB). The rs6265 (c.196G > A, p.Val66Met) polymorphism in the BDNF gene was previously associated with impaired secretion of this neurotrophin. The aims of the present study were to analyze the possible association of the BDNF: rs6265 polymorphism with OAB risk and with the response to a single intradetrusor injection of botulinum neurotoxin type A (BoNT/A) in female patients. The study group comprised 160 OAB females, and the control group comprised 359 healthy females. Urodynamic parameters, frequencies of OAB symptoms, and scores from ICIQ-OAB and ICIQ-LUTS-QoL questionnaires were recorded before BoNT/A injection and six months after. Genotyping of BDNF: rs6265 polymorphism was performed using TaqMan real-time polymerase chain reaction. No statistically significant differences in the distribution of BDNF genotypes or alleles between OAB patients and healthy controls were found. No significant differences among OAB subjects regarding BDNF polymorphism were found in terms of clinical symptoms, scores of both questionnaires, and urodynamic parameters. These results do not support the hypothesis that BDNF: rs6265 polymorphism in Polish females with OAB is associated with susceptibility to this condition and with response to BoNT/A treatment.

Indexed as

Botulinum Toxins, Type ABrain-Derived Neurotrophic FactorPolymorphism, Single NucleotideUrinary Bladder, OveractiveAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHumansMiddle AgedBDNF protein, humanBotulinum Toxins, Type ABrain-Derived Neurotrophic FactorBotulinum neurotoxin-ABrain-derived neurotrophic factorGenetic polymorphismOveractive bladder

Identifiers

PMID42315574
PMCPMC13554184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.